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Research
Perfluorooctanoic acid (PFOA) is a member
of a class of perfluorinated compounds that
are used widely in consumer products and
industrial applications including surfactants,
lubricants, textile coatings, food packaging,
and ﬂame retardants. PFOA is also a degrada-
tion product of other fluoropolymers that is
highly resistant to further metabolic and envi-
ronmental breakdown. Because of its wide-
spread occurrence and chemical stability,
there are increasing concerns about the envi-
ronmental persistence and accumulation of
PFOA measured in terrestrial and aquatic
biota and in human serum (Calafat et al.
2007; Houde et al. 2006; Prevedouros et al.
2006). Estimation of PFOA half-lives in
serum varies broadly, depending on species
and sex, and ranges from days in rats (Vanden
Heuvel et al. 1991) and cynomolgus monkeys
(Butenhoff et al. 2004) to almost 4 years in
occupationally exposed humans (Olsen et al.
2007). Although some perﬂuorinated chemi-
cals have been voluntarily removed from the
market by manufacturers over concerns
related to environmental occurrence and sta-
bility, PFOA is still produced commercially,
and its potential risk to humans continues to
be evaluated (U.S. Environmental Protection
Agency 2006).
PFOA is a potent peroxisome proliferator
(PP) similar to other perﬂuorinated chemicals
(Sohlenius et al. 1992). Overall, PPs comprise
a structurally diverse group of nongenotoxic
carcinogens including certain hypolipidemic
drugs [cloﬁbrate (CLOF), ciproﬁbrate], indus-
trial plasticizers (phthalates), herbicides
(phenoxyacetic acids), and organic solvents
(trichloroethylene). PPs are known to cause
hepatomegaly, altered cholesterol homeostasis,
increased number and size of peroxisomes, and
increased β-oxidation and ω-oxidation of fatty
acids in peroxisomes and microsomes, respec-
tively, in susceptible animal models (Moody
et al. 1991). Prolonged exposure to PPs,
including PFOA, also results in increased liver
tumor incidence in rodents (Abdellatif et al.
1991). Although the causative link between
peroxisome proliferation and hepatocarcino-
gesis has not been ﬁrmly established, PPs are
thought to enhance liver tumors in rodent
models as a result of peroxisome proliferation
through sustained oxidative stress and regula-
tion of cellular proliferation and differentiation
(Reddy and Rao 1989). Many PP-mediated
effects occur through ligand-dependent activa-
tion of the nuclear receptor, PP-activated recep-
tor alpha (PPARα), and consequently do not
occur in PPARα-null mice (Peters et al. 1997). 
Despite the apparent toxicity of PFOA
and other PPs in rodents, humans are rela-
tively insensitive to peroxisome proliferation
by this class of compounds (Fruchart et al.
1998). In fact, marked species differences
exist in susceptibility to peroxisome prolifera-
tion such that rodents are highly sensitive,
whereas humans and certain other models,
including rainbow trout, guinea pigs, and
nonhuman primates, show little to no evi-
dence of peroxisome proliferation (Butenhoff
et al. 2002; Lake et al. 1989; Orner et al.
1996). The insensitivity of humans to PP
toxicity is attributed to the approximately 10-
fold lower expression of PPARα receptor in
liver compared with mouse (Palmer et al.
1998). It is generally accepted that humans
are likely refractory to hepatocarcinogenesis
caused by peroxisome proliferation via a
PPARα mode of action; however, there is
also accumulating evidence for PFOA toxicity
independent of peroxisome proliferation. For
example, PFOA induces Leydig-cell and pan-
creatic acinar-cell tumors in chronic rodent
bioassays, similar to some other PPs (Biegel
et al. 2001). Leydig-cell tumor formation was
correlated with elevated serum estradiol and
inhibition of testosterone synthesis rather
than peroxisome proliferation in these cells.
PFOA was also shown to cause hepatomegaly
in PPARα-null mice and cynomolgus mon-
keys without an increase in typical measures
of peroxisome proliferation, suggesting that
PFOA can cause liver toxicity presumably
independent of PPARα, which may be rele-
vant for humans (Butenhoff et al. 2002; Yang
et al. 2002). These studies show the potential
for significant toxicity by PFOA to occur
independent of peroxisome proliferation and
indicate that use of PP-insensitive species in
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BACKGROUND: Perﬂuorooctanoic acid (PFOA) is a potent hepatocarcinogen and peroxisome prolif-
erator (PP) in rodents. Humans are not susceptible to peroxisome proliferation and are considered
refractory to carcinogenesis by PPs. Previous studies with rainbow trout indicate they are also
insensitive to peroxisome proliferation by the PP dehydroepiandrosterone (DHEA), but are still
susceptible to enhanced hepatocarcinogenesis after chronic exposure. 
OBJECTIVES: In this study, we used trout as a unique in vivo tumor model to study the potential for
PFOA carcinogenesis in the absence of peroxisome proliferation compared with the structurally
diverse PPs clofibrate (CLOF) and DHEA. Mechanisms of carcinogenesis were identified from
hepatic gene expression proﬁles phenotypically anchored to tumor outcome.
METHODS: We fed aﬂatoxin B1 or sham-initiated animals 200–1,800 ppm PFOA in the diet for
30 weeks for tumor analysis. We subsequently examined gene expression by cDNA array in animals
fed PFOA, DHEA, CLOF, or 5 ppm 17β-estradiol (E2, a known tumor promoter) in the diet for
14 days. 
RESULTS: PFOA (1,800 ppm or 50 mg/kg/day) and DHEA treatments resulted in enhanced liver
tumor incidence and multiplicity (p < 0.0001), whereas CLOF showed no effect. Carcinogenesis
was independent of peroxisome proliferation, measured by lack of peroxisomal β-oxidation and
catalase activity. Alternately, both tumor promoters, PFOA and DHEA, resulted in estrogenic gene
signatures with strong correlation to E2 by Pearson correlation (R = 0.81 and 0.78, respectively),
whereas CLOF regulated no genes in common with E2. 
CONCLUSIONS: These data suggest that the tumor-promoting activities of PFOA in trout are due to
novel mechanisms involving estrogenic signaling and are independent of peroxisome proliferation.
KEY WORDS: clofibrate, dehydroepiandrosterone, estradiol, hepatocarcinogenesis, microarray,
perfluorooctanoic acid, peroxisome proliferation, rainbow trout. Environ Health Perspect
116:1047–1055 (2008). doi:10.1289/ehp.11190 available via http://dx.doi.org/ [Online 9 May 2008]evaluation of novel PFOA effects may be
important for identification of mechanisms
that can be extrapolated to humans.
In this study, we examined the in vivo
effects of chronic PFOA exposure on hepato-
carcinogenesis in rainbow trout, a model used
for chemically induced liver cancer in humans
for over 40 years (Bailey et al. 1996). PFOA
was evaluated as both a complete carcinogen
and as a promoter of aflatoxin B1 (AFB1)-
induced liver cancer compared with two
structurally diverse PPs, CLOF and dehydro-
epiandrosterone (DHEA). CLOF is a hypo-
lipidemic drug and known PPARα agonist
that acts as a complete carcinogen in rodents
(Reddy and Qureshi 1979). DHEA, an
adrenal steroid in humans, is classiﬁed as a PP
based on its ability to induce peroxisome pro-
liferation in rodents, but appears to operate
independently of PPARα (Webb et al. 2006).
Our laboratory previously demonstrated that
rainbow trout are insensitive to peroxisome
proliferation by DHEA but are still respon-
sive to induction of liver cancer by this com-
pound (Orner et al. 1995). Rainbow trout are
also susceptible to tumor enhancement by
pro-oxidants (Kelly et al. 1992), which is a
proposed mechanism for PP-induced liver
cancer in rodents. The goals of this study
were to a) determine the potential for PFOA-
mediated carcinogenesis in vivo in the absence
of peroxisome proliferation, b) investigate
whether this mode of action is common
across a class of known PPs or PPARα ago-
nists, and c) identify potential mechanisms of
carcinogenesis from phenotypic anchoring of
global gene expression proﬁles to tumor out-
come. Toxicogenomic proﬁling has been suc-
cessfully used in rainbow trout to examine
mechanisms of chemical hepatocarcinogenesis
(Tilton et al. 2005, 2006, 2007) and has also
been used in other models to determine
effects of PFOA in liver (Guruge et al. 2006).
Overall, we determined that PFOA can
enhance hepatocarcinogenesis postinitiation
in the trout model at 1,800 ppm in the diet,
or 50 mg/kg/day. However, tumor promo-
tion was not correlated to peroxisome prolif-
eration, but rather to estrogenic signaling in
trout liver, which is a novel mechanism of
carcinogenicity reported for PFOA in a PP-
insensitive species.
Materials and Methods
Materials and animals. Analytical-grade AFB1,
17β-estradiol (E2), and DHEA were purchased
from Sigma Chemical Co. (St. Louis, MO).
CLOF and PFOA were purchased from Fluka
Chemical Corp. (St. Louis, MO). All other
compounds were purchased from Sigma
Chemical Co. unless otherwise stated. Mt.
Shasta strain rainbow trout (Oncorhynchus
mykiss) were hatched and reared at the Oregon
State University Sinnhuber Aquatic Research
Laboratory in 14°C flowing well water on a
12:12 hr light:dark cycle. All animal protocols
were performed in accordance with Oregon
State University Institutional Animal Care and
Use Committee guidelines. Animals were
treated humanely and with regard for allevia-
tion of suffering.
Tumor experiment, necropsy, and
histopathology. Approximately 1,000 fry were
initiated at 10 weeks posthatch with an aque-
ous exposure to 0.01 ppm AFB1 for 30 min.
Sham-exposed trout were exposed to vehicle
alone (0.01% ethanol) and served as non-
initiated controls for each treatment. After ini-
tiation, fry were fed Oregon Test Diet (OTD),
a semipuriﬁed casein-based diet, for 3 months
(Lee et al. 1991). Trout were then randomly
(within initiator group) divided into experi-
mental treatment groups (140 animals/treat-
ment) and fed experimental diets containing
200 or 1,800 ppm PFOA, 1,800 ppm CLOF,
or 1,800 ppm DHEA ad libitum (2.8–5.6%
body weight) 5 days/week for 6 months, a pro-
tocol similar to that previously described for
DHEA (Orner et al. 1995). The PFOA con-
centrations in the diet for 200 and 1,800 ppm
are equivalent to 5 and 50 mg/kg/day, respec-
tively. Diets were prepared monthly and stored
frozen at –20°C until 2–4 days prior to feed-
ing, when diets were allowed to thaw at 4°C. 
At 9 months postinitiation, juvenile fish
were euthanized by deep anesthesia with
250 ppm tricaine methanesulfonate and sam-
pled for liver tumors over a 2-day period. Livers
were ﬁxed in Bouin’s solution for 2–7 days for
histologic identification and examination of
tumors with hematoxylin and eosin. Neoplasms
were classiﬁed by the criteria of Hendricks et al.
(1984). The effect of dietary PPs on tumor
incidence was modeled by logistic regression
(GENMOD procedure, SAS version 9.1; SAS
Institute, Cary, NC). Tumor multiplicity data
(number of tumors per tumor-bearing animal)
were analyzed by the Kruskal-Wallis test with
p-values based on the exact permutation
distribution (StatXact, version 2.04; Cytel
Software, Corp., Cambridge, MA). 
Microarray experiment. Juvenile trout,
12–18 months of age, were maintained in sepa-
rate 375-L tanks (three tanks) for each treat-
ment, with ﬁve ﬁsh per tank. Animals were fed
a maintenance ration (2.8% wt/tw) of OTD.
Administration of experimental diets contain-
ing 500 or 1,800 ppm PFOA, 1,800 ppm
CLOF, 750 ppm DHEA, 5 ppm E2, or 0.1%
dimethyl sulfoxide (DMSO) vehicle control
was carried out for 14 days. The concentrations
of E2 and DHEA were chosen based on their
ability to maximally induce vitellogenin (VTG)
and/or act as hepatic tumor promoters in trout
(Nunez et al. 1989). On day 15, ﬁsh were euth-
anized by deep anesthesia with 250 ppm tri-
caine methanesulfonate. Approximately
100 mg liver tissue from individual fish was
minced, stored in TRIzol Reagent (Invitrogen,
Carlsbad, CA) and quick-frozen in liquid nitro-
gen for gene expression analysis. The rest of the
liver was quick-frozen in liquid nitrogen for
enzyme assays.
Total hepatic RNA was isolated from indi-
vidual trout liver using TRIzol Reagent, fol-
lowed by cleanup with RNeasy Mini Kits
(QIAGEN, Valencia, CA) according to manu-
facturer instructions. Equal amounts of RNA
(micrograms) were pooled from each of the
five fish per tank (three tanks or biological
replicates) for every treatment. RNA was
pooled from individual animals to reduce
variability across replicates due to individual
differences, allowing for analysis of gene
expression changes that are representative of
the population. A reference sample was cre-
ated from RNA pooled from 15 vehicle con-
trol fish. RNA quality and quantity were
assessed by agarose gel electrophoresis, spectro-
photometric absorbency at 260/280 nm, and
bioanalyzer trace (Bioanalyzer 2100; Agilent,
Palo Alto, CA).
Peroxisomal β-oxidation and catalase
activity. The β-oxidation of palmitoyl coen-
zyme A (CoA) was measured by the spectro-
photometric method of Mitchell et al. (1985)
in peroxisomal fractions prepared by differential
centrifugation, as described previously (Orner
et al. 1995). Enzyme activity was measured at
340 nm (20°C) and expressed as amount of
NAD+ (nicotinamide adenine dinucleotide)
reduced per minute per milligram of protein.
Catalase activity was measured spectrophoto-
metrically by the decay of hydrogen peroxide,
as described previously (Aebi 1984; Orner et al.
1995). Enzyme activity was measured at
240 nm (20°C) and expressed as speciﬁc activ-
ity (micromoles per minute per milligram of
protein). Protein was quantiﬁed by the method
of Lowry et al. (1951). 
Serum VTG and E2. VTG was quantiﬁed
in trout serum by enzyme-linked immuno-
sorbent assay (ELISA), as previously described
(Tilton et al. 2006). Protein concentrations
were determined by the method of Lowry et al.
(1951). VTG concentrations were determined
by optical density on a SpectraMax 190 plate
reader (Molecular Devices, Sunnyvale, CA)
based on comparison with a trout VTG stan-
dard curve with a detection limit for this assay
of 6.25 ng/mL. Serum VTG was also meas-
ured by Western blot using the same antibody
to capture images from representative samples
(Oganesian et al. 1999). E2 was quantiﬁed in
trout serum by enzyme immunosorbent assay
according to the manufacturer protocol
(Cayman Chemical, Ann Arbor, MI). 
Microarray hybridization and analysis.
Rainbow trout 70-mer oligonucleotide arrays
(OSUrbt, version 2.0) containing 1,672 ele-
ments, representing approximately 1,400 genes,
were created at Oregon State University.
Tilton et al.
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have been described previously (Tilton et al.
2005). Hybridizations were performed with
the Genisphere Array 350 kit and instructions
(Genisphere, Hatﬁeld, PA) using standard ref-
erence design with dye swapping as described
(Tilton et al. 2007). Data were background-
subtracted and normalized by locally weighted
scatterplot smoothing (LOWESS), which is
recommended for two-color experiments to
eliminate dye-related artifacts and produce
ratios that are not affected by signal intensity
values. Stringent criteria were used to ﬁlter for
genes that were regulated at least 1.8-fold con-
sistently in all features from biological repli-
cates and had a p-value < 0.05 by Welch’s
t-test (GeneSpring version 6; Silicon Genetics,
Redwood City, CA). Genes that met these cri-
teria were minimally categorized based on
function using Gene Ontology (Gene
Ontology Consortium 2008) and OMIM
[National Center for Biotechnology
Information (NCBI) 2008c] databases for
putative homolog descriptions. Hierarchical
clustering of gene expression proﬁles was per-
formed in GeneSpring, and comparisons of
microarray and real-time polymerase chain
reaction (PCR) gene regulation were per-
formed with GraphPad Prism (GraphPad
Software, San Diego, CA).
Real-time quantitative reverse transcription
(qRT)-PCR. To assess the authenticity of
results from the microarray analyses, we also
analyzed mRNAs for select genes using real-
time RT-PCR. Total RNA was isolated as
described above and was treated with DNase
(Invitrogen) according to manufacturer’s proto-
col. cDNA was synthesized from 2 µg RNA
with an oligo (dT)18 primer using SuperScript
II (Invitrogen) following the manufacturer’s
instructions, with a final volume of 100 µL.
Synthesized cDNAs (1 µL) were used as tem-
plates for ampliﬁcation of speciﬁc gene prod-
ucts in total volumes of 20 µL containing
1X SYBR Green master mix (DyNAmo qPCR
kit; Finnzymes, Espoo, Finland) and 0.3 µM of
each primer. Primer sequences were as follows:
5´-GAGTTTGGGCAGGTGGTG-3´ and
5´-TGGTGCGGTTTGGTAGGT-3´ for
cytochrome P450 family 1A [CYP1A; Dana-
Farber Cancer Institute (DFCI 2008) Gene
Index ID TC63282]; 5´-GTGTCAACTC-
TAATCTAGTGCCC-3´ and 5´-CCGTCC-
CTGATTGAAGTGAC-3´ for CYP2K5
(TC95312); 5´-TAAAAGTTGCACAAGTT-
TCC-3´ and 5´-AAAGGTCCGTTCT-
GATCGTC-3´ for cathepsin D (CTSD
(TC128395); 5´-AGCTCCTGCTCCT-
GCTCT-3´ and 5´-GGAATGGGCATCTG-
GTCT-3´ for estrogen receptor (ER)-α (ESR1;
TC94766); 5´-CCAACCAAACGCTACC-
GAAC-3´ and 5´-CCAGATTCCATCTCAC-
CTT-3´ for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; TC94858); and
5´-TTGCCTTTGCCAACATCGAC-3´ and
5´-CGGACATTGACGTATGCTTT-3´ for
VTG (TC47576). PCR was performed using a
DNA Engine Cycler and Opticon 2 Detector
(MJ Research, Waltham, MA). DNA ampliﬁ-
cation was quantified (picograms) from the
C(T) value based on standard curves to ensure
that quantiﬁcation was within a linear range.
Standards were created from gel-puriﬁed PCR
products (QIAX II; QIAGEN) for each primer
set after quantification with the PicoGreen
dsDNA Quantiﬁcation Kit (Molecular Probes,
Eugene, OR) and serial dilutions ranging from
0.25 to 100 ng DNA. All signals were normal-
ized against GAPDH, and ratios were calcu-
lated for treated samples compared with
control. Because expression of GAPDH was
not altered by treatment based on either
microarray analysis or RT-PCR, we found it to
be an appropriate housekeeping gene for nor-
malization in this study. 
Results
Tumor study. Exposure to experimental diets
containing 1,800 ppm PFOA (equivalent to
50 mg/kg/day) or DHEA significantly
(p < 0.0001) enhanced the incidence of liver
tumors in AFB1-initiated trout above control
animals (Figure 1). In addition, the multiplic-
ity increased signiﬁcantly (p < 0.0001) in both
PFOA- and DHEA-fed trout (Figure 1A).
Some animals fed promotional diets after ini-
tiation with AFB1 had more than six tumors
per liver, compared with animals on the con-
trol diet, most of which had 1–2 tumors per
liver (in tumor-bearing animals). In contrast,
postinitiation feeding with CLOF resulted in
no increase in either tumor incidence or mul-
tiplicity. The historical spontaneous liver
tumor incidence in 9-month-old trout fed
control diet is 0.1%. Consequently, no
tumors were observed in noninitiated animals
fed control, CLOF, or PFOA diets. However,
consumption of 1,800 ppm DHEA in the
diet for 6 months resulted in 20% tumor
incidence in noninitiated animals, which is
consistent with previous observations in our
laboratory that DHEA acts as a complete
hepatocarcinogen in trout (Table 1) (Orner
et al. 1995). Histologic examination of liver
tumors confirmed previous findings from
our laboratory that mixed carcinoma is the
Tumor promotion by PFOA
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Figure 1. Effects of test compounds on tumor incidence, serum VTG, and serum E2 compared with DMSO
vehicle control. (A) Tumor incidence and multiplicity after exposure to CLOF, DHEA, or PFOA in the diet for
6 months compared with control (postinitiation by immersion in 10 ppb AFB1 (each treatment consisted of
a single tank of 68–100 individuals). (B) Serum VTG in trout after exposure to E2, DHEA, and PFOA in the
diet for 5 days as determined by Western blot (representative images shown) and ELISA (n = 4). (C) Serum
E2 in trout after exposure to E2, DHEA, and PFOA in the diet for 14 days, as determined by enzyme immuno-
sorbent assay. For (B) and (C), pools of blood plasma were obtained from five individual males in each
replicate tank (n = 3). 
**p < 0.01 compared with control by one-way ANOVA with Dunnett’s multiple comparison test. #p < 0.0001 for tumor inci-
dence and ##p < 0.0001 for multiplicity compared with control, calculated by logistic regression analysis and Kruskal-
Wallis test, respectively. 
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Table 1. Effects of PPs on tumor type.
Treatmenta Percent tumor Tumor class (%)
(initiation/promotion) incidence MC HCC CCC MA HCA Ch BF
None/none 0 0 0 0 0 0 0 0
None/CLOF 0 0 0 0 0 0 0 0
None/DHEA 20* 67 25 0 4 4 0 0
None/low PFOA 0 0 0 0 0 0 0 0
None/high PFOA 0 0 0 0 0 0 0 0
AFB1/none 36 54 10 10 5 3 5 12
AFB1/CLOF 32 15 0 74 0 2 7 2
AFB1/DHEA 100* 72 25 < 1 0 1 1 < 1
AFB1/low PFOA 34 50 11 16 5 0 14 5
AFB1/high PFOA 71* 37 46 1 2 8 1 5
Abbreviations: BF, basophilic foci; CCC, cholangiocellular carcinoma; Ch, cholangioma; HCA, hepatocellular adenoma;
HCC, hepatocellular carcinoma; MA, mixed adenoma; MC, mixed carcinoma. 
aAnimals were initiated with 10 ppb AFB1 as fry and fed control diet for 3 months, followed by 6-month exposure to con-
trol, 1,800 ppm CLOF, 1,800 ppm DHEA, or 200 or 1,800 ppm PFOA in the diet postinitiation (promotion). *p < 0.05 compared
with control animals (within initiator group) by logistic regression analysis. predominant tumor type in AFB1-initiated
trout (Table 1) (Oganesian et al. 1999).
Tumor type remained consistent among all
treatments except in animals fed CLOF post-
initiation, which resulted in a shift in pre-
dominant tumor type to cholangiocellular
carcinoma. Both DHEA and PFOA also pro-
duced hepatomegaly, as measured by liver
somatic index (LSI; liver weight ÷ body
weight × 100). Trout fed 1,800 ppm PFOA
or DHEA for either 2 or 10 weeks had a sig-
niﬁcantly greater LSI compared with controls
(p < 0.05) (Table 2).
Despite signiﬁcant tumor promotion and
hepatomegaly in trout liver after PFOA treat-
ment, both of which are characteristic of PPs,
typical enzymatic measurements of liver per-
oxisomal activity were not elevated by PFOA.
Analysis of hepatic peroxisomal palmitoyl
CoA oxidase activity in trout fed PPs for
6 months provided no evidence that CLOF,
DHEA, or PFOA induced peroxisome enzy-
matic activities (Table 2). In fact, signiﬁcant
reduction in β-oxidation was observed for
1,800 ppm PFOA and DHEA (p < 0.01).
Similarly, β-oxidation and catalase activity
were not increased in liver peroxisomes and
liver homogenates of animals from the
microarray experiment after 14-day exposure
to experimental diets (Table 2). Ultra-
structural examination of treated livers
revealed no evidence of increased size or num-
ber of peroxisomes (data not shown). Because
DHEA was previously found to induce
hepatic VTG, a glucolipoprotein egg yolk pre-
cursor produced in response to estrogen
(Orner et al. 1996), animals exposed to PFOA
were examined for induction of this estrogenic
marker. VTG was subsequently detected in
serum of animals treated with 1,800 ppm
PFOA or 750 ppm DHEA in the diet for
5 days compared with E2, which was included
as a positive control, indicating that these
compounds may induce an estrogenic
response in trout (Figure 1B). 
Gene expression analysis. To evaluate the
mechanism of tumor enhancement by PFOA,
the OSUrbt, version 2.0, array was used to
characterize transcriptional profiles in liver
samples from animals treated with 1,800 ppm
CLOF, 750 ppm DHEA, 500 (low) and
1,800 (high) ppm PFOA, or 5 ppm E2 in
the diet compared with control animals.
Supplemental raw data files are available
online through Gene Expression Omnibus
accession no. GSE7837 (NCBI 2008b). Array
hybridizations were performed with a com-
mon reference sample using dye swapping,
and ﬁnal fold-change values were calculated as
a ratio to control animals. Bidirectional hierar-
chical clustering of genes differentially regu-
lated in at least one treatment group
(Figure 2A) indicated similarities in the tran-
scriptional proﬁles for E2, PFOA, and DHEA
treatments. This is supported by pairwise
analysis of all 1,672 features on the array using
Pearson correlation, which demonstrated
strong correlations in gene patterns between
E2 and low PFOA, high PFOA, and DHEA
[R = 0.69, 0.81, and 0.79 (two-tailed
p < 0.0001), respectively] (Figure 2B). In con-
trast, gene proﬁles from CLOF had a low cor-
relation with E2 (R = 0.26) and high PFOA
(R = 0.45). Genes were considered differen-
tially expressed if their mRNA levels changed
≥ or ≤ 1.8-fold compared with controls
(p < 0.05) among biological replicates
(Table 3). Transcriptional proﬁles for PFOA
were typical of an estrogenic response in trout
liver (Tilton et al. 2006) and strongly over-
lapped with the profile for E2 as determined
by principal component analysis applied on
condition (Figure 2C). Transcripts encoding
vitellogenic liver proteins were the most sensi-
tive markers for the estrogenic response in
trout; however, a number of genes important
for cell proliferation, protein transport,
immune function, and metabolism were also
differentially regulated by PFOA, DHEA, and
E2 treatments. Interestingly, PFOA did not
regulate many genes in common with CLOF,
another PPAR agonist. CYP2K5 was signifi-
cantly up-regulated by both CLOF and PFOA
and was down-regulated by E2 and DHEA.
Microarray transcripts for carnitine palmitoyl-
transferase II, acetyl-CoA acetyltransferase 2,
and catalase, as measures of β-oxidation and
hydrogen peroxide generation, were not differ-
entially regulated (up or down) by treatment
with the PPs or E2, supporting the lack of
treatment-related elevation of peroxisomal
enzyme activities observed in trout (Table 3).
The ability of PFOA and DHEA to alter
serum E2 concentrations was explored as a
possible mechanism for their estrogenic activ-
ity. Serum E2 was signiﬁcantly elevated in ani-
mals fed 5 ppm E2 or 750 ppm DHEA in the
diet for 14 days; however, serum E2 in PFOA-
treated animals was not statistically different
from control animals (Figure 1C), suggesting
that the estrogenic effect of PFOA was not
indirectly caused by altered serum E2 levels.
Expression of select genes differentially
increased or decreased by microarray analysis,
including CYP2K5, VTG, CYP1A, CTSD,
and ESR1, was conﬁrmed by qRT-PCR using
SYBR Green (Figure 3). Overall, we were able
to conﬁrm gene expression proﬁles measured
by oligonucleotides microarray analysis using
qRT-PCR. These data indicate that our strict
criteria for determining differential gene regu-
lation by array resulted in detection of mean-
ingful changes that could be validated by
other methods.
Discussion
This study is the ﬁrst report of tumor enhance-
ment by PFOA in a model that is insensitive to
peroxisome proliferation. Tumor promotion
was not related to the function of PFOA as a
PP or PPARα agonist but was phenotypically
linked to estrogenic gene signatures in trout
liver. The lack of tumor enhancement by
CLOF is also a novel observation in trout and
is supported by data indicating that another
potent PP and PPARα agonist, Wy-14,643,
does not enhance tumor incidence in trout after
chronic exposure postinitiation (Carpenter H,
personal communication). The tumor response
to DHEA was similar to that published previ-
ously by our laboratory and confirms that
DHEA is both a complete hepatocarcinogen
and a tumor promoter in trout without induc-
ing peroxisome proliferation (Orner et al.
1995). Chronic PFOA exposure causes liver
tumors in rats and is associated with increased
hepatomegaly, increased hepatic β-oxidation
activity, and no change in hepatic cell prolifera-
tion (Biegel et al. 2001). These effects are typi-
cal of PPs in animals that are susceptible to
Tilton et al.
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Table 2. Effects of PPs on liver weight and enzyme markers.
Treatmenta LSIb Palmitoyl CoA β-oxidationc Catalased
Tumor study
Control 1.572 ± 0.370 36.8 ± 5.4
1,800 ppm CLOF 1.381 ± 0.270 27.1 ± 3.4
1,800 ppm DHEA 4.889 ± 1.041*** 10.0 ± 4.6**
200 ppm PFOA 1.631 ± 0.259 23.8 ± 3.6
1,800 ppm PFOA 2.440 ± 0.210*** 15.2 ± 1.4**
Microarray study
Control 1.172 ± 0.039 63.5 ± 11.9 1033.0 ± 120.3
1,800 ppm CLOF 1.429 ± 0.095 52.3 ± 8.9 1105.0 ± 64.1
750 ppm DHEA 1.963 ± 0.101** 39.5 ± 2.5 633.1 ± 52.3*
500 ppm PFOA 1.513 ± 0.061* 58.6 ± 12.6 883.1 ± 28.9
1,800 ppm PFOA 1.543 ± 0.129* 26.5 ± 12.3 790.6 ± 104.5
5 ppm E2 1.930 ± 0.262** 23.3 ± 7.0 656.2 ± 45.5*
aTumor study animals (n = 4; pool of three animals each) were initiated with 10 ppb AFB1 as fry and fed control diet for
3 months, followed by 10-week (LSI) or 6-month (β-oxidation) exposure to indicated treatments in the diet postinitiation
(promotion). Microarray study animals (n = 3) were exposed as juveniles to indicated treatments in the diet for 14 days.
bMean ± SD. cNanomoles of activity per minute per milligram protein (mean ± SE). dMicromoles of activity per minute per
milligram protein (mean ± SE). 
*p < 0.05, **p < 0.01, and ***p < 0.001 compared with respective control values by one-way ANOVA with Dunnett’s multi-
ple comparison test. peroxisome proliferation and further include
increased size and number of peroxisomes and
induction of peroxisomal and microsomal
enzymes involved in β-oxidation and ω-oxida-
tion of fatty acids (Moody et al. 1991). In the
present study, PFOA exposure in trout
resulted in hepatomegaly but no increase in
the size or number of peroxisomes or in bio-
chemical or transcriptional markers of peroxi-
some proliferation. 
Compared with rodents, the effects
observed in trout are more similar to those
reported in nonhuman primates after oral
exposure to the PFOA precursor ammonium
perfluorooctanoate. In a study of male
cynomolgus monkeys exposed to 3–30 mg/kg/
day for 26 weeks, Butenhoff et al. (2002)
observed increased liver weights but little or no
histopathologic evidence of liver toxicity,
changes in enzyme markers of peroxisome pro-
liferation, or changes in serum hormone levels.
The increase in monkey liver weights was
attributed in part to hepatocellular hypertro-
phy and mitochondrial proliferation, as
demonstrated by elevated succinate dehydroge-
nase activity. Succinate dehydrogenase was
transcriptionally up-regulated in trout liver
after exposure to PFOA, DHEA, and E2, all of
which resulted in hepatomegaly in uninitiated
animals. In addition, PFOA did not act as a
complete carcinogen in either cynomolgus
monkeys or trout after chronic exposure. One
notable exception may be that cell prolifera-
tion, as measured by proliferating cell nuclear
antigen (PCNA), was not elevated in cynomol-
gus liver at the end of 26 weeks, even though
PFOA was detected in both liver and serum
(Butenhoff et al. 2002). Although PCNA was
not measured in the present study, previously
it has been found to be induced in trout liver
after 2-week exposure to DHEA, E2, and other
compounds that result in estrogenic gene
signatures (Orner et al. 1996; Tilton SC,
unpublished data). The lack of PCNA as a
proliferative marker in monkeys may indicate
some differences in the mechanism for liver
hypertrophy between trout and primates and
should be further explored.
PPs are thought to cause cancer through
the metabolism of long-chain fatty acids by
the peroxisomal β-oxidation system, which
generates hydrogen peroxide and can result in
DNA damage. However, we found no evi-
dence of oxidative stress after exposure to PPs
in trout. Catalase was not increased by any PP
treatment in this experiment. Glutathione per-
oxidase, another measure of oxidative stress,
was only up-regulated by treatments that
resulted in an estrogenic response and thus
was not speciﬁc to the PP class of compounds.
Interestingly, there were few transcriptional
changes by PFOA in common with the other
PPARα agonist, CLOF, and independent of
E2. These changes included up-regulation of
CYP2K5, prostaglandin D synthase, and to a
lesser extent, carbonyl reductase. Although the
function of CYP2K5 in trout is unknown, this
gene was regulated by PPARα agonists and E2
in a manner that has been reported previously
for CYP2K1, lauric acid ω-hydroxylase, which
is known to be mediated by PPARα and
shares approximately 80% sequence identity
with CYP2K5 (Buhler et al. 2000; Kennedy
et al. 2004). However, CYP2K1 itself was not
transcriptionally regulated by any treatments
in the present study, suggesting that these
enzymes have different activities in trout liver.
Both prostaglandin D synthase and carbonyl
reductase are involved in the signaling and
metabolism of prostainoids, a pathway that
has been associated with development of
Tumor promotion by PFOA
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Figure 2. Hepatic gene expression analysis after dietary exposure to 0.1% DMSO (control), 500 or 1,800 ppm PFOA, 750 ppm DHEA, 1,800 ppm CLOF, or 5 ppm E2 for
14 days. PCA, principal components analysis. (A) Bidirectional hierarchical clustering of hepatic gene expression in trout by Euclidean distance. Results are
shown as fold change (log2) of control of dye-swapped slides for biological replicates (n = three per treatment). Heatmap reﬂects expression proﬁles for genes
differentially regulated 1.8-fold up or down (p < 0.05) in at least one treatment group. Red indicates up-regulation; green, down-regulation; black, unchanged
expression; and grey, missing values. (B) Pairwise correlations of hepatic gene proﬁles; values are fold change (log2) compared with control and were plotted to
generate Pearson correlation coefﬁcients (R) among the treatments (p < 0.0001). Lines indicate least-squares linear regression. (C) PCA on condition. Symbols
represent biological replicates (n = 3), and ovals indicate overlap among E2, PFOA, and DHEA treatments. 
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R = 0.69 R = 0.26 R = 0.45hepatocellular carcinoma involving cyclo-
oxygenase-2 (Wu 2006). Therefore, PFOA
exposure resulted in some transcriptional
responses that were specific for PPARα ago-
nists and distinct from E2; however, they were
not correlated with tumor enhancement by
DHEA and PFOA. 
Previously, we found that rainbow trout
are very sensitive to promotion of hepatocar-
cinogenesis by E2 and other estrogenic com-
pounds (Nunez et al. 1989; Tilton et al. 2007).
The mechanism by which PFOA induces an
estrogenic response in trout liver is currently
unknown; however, some links between PPs
and estrogen-mediated carcinogenesis have
been reported. For example, ﬁbrates can stimu-
late the esterification of E2 with fatty acids,
which promote the storage and prolonged
release of E2 from fatty tissue, enhancing cell
proliferation in mammary gland (Yu et al.
2001). However, this mechanism was not
Tilton et al.
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Table 3. Select genes differentially regulated in trout liver. 
Treatment (ppm) 
CLOF DHEA PFOA PFOA E2
Array ID DFCI IDa Gene name (accession number, species)b Control 1,800 750 500 1,800 5
Liver-speciﬁc proteins (vitellogenesis)
OmyOSU208 TC94769 Vitellogenin precursor (Q92093; O. mykiss) –0.06 0.52 3.90* 2.68* 4.15* 3.94*
OmyOSU203 TC47576 Vitellogenin precursor (X92804; O. mykiss) –0.12 0.41 3.49* 2.54* 3.53* 3.47*
OmyOSU222 TC47576 Vitellogenin precursor (X92804; O. mykiss) –0.19 0.29 3.22* 2.35* 3.43* 3.35*
OmyOSU248 TC47577 Vitellogenin (X92804; O. mykiss) –0.27 0.23 2.98* 2.29* 3.12* 3.08*
OmyOSU1552 TC55460 Vitelline envelope protein gamma (AF231708; O. mykiss) 0.05 0.63 2.78* 2.63* 2.96* 2.84*
OmyOSU1542 TC85700 Zona radiata structural protein (AF407574; O. mykiss) –0.04 0.60 2.72* 2.20* 2.63* 2.72*
Cell proliferation (signal transduction, growth factors, and apoptosis)
OmyOSU212 TC70106 TATA-binding protein (AY168633; Danio rerio) 0.07 0.14 2.54* 1.36* 3.40* 3.18*
OmyOSU244 NP543968 Estrogen receptor-β (ESR2; AJ289883; O. mykiss) 0.02 0.21 1.92* 1.34* 2.13* 2.13*
OmyOSU151 TC88754 Estrogen receptor-α (ESR1; M31559; O. mykiss) 0.06 0.43 1.55* 0.72 2.08* 1.89*
OmyOSU150 TC94766 Estrogen receptor-α (ESR1; P16058; O. mykiss) 0.07 0.47 0.88* 0.59 1.46* 1.27*
OmyOSU673 TC94766 Estrogen receptor-α (ESR1; P16058; O. mykiss) 0.01 0.79 0.81 0.48 1.37* 1.00*
OmyOSU800 TC72880 Nonreceptor tyrosine kinase 2 (TYK2; AF173032; Mus musculus) –0.03 0.07 1.07* 0.54 1.49* 1.44*
OmyOSU915 TC78497 Cysteine-rich with EGF-like domains 1 (CR751234; D. rerio) 0.08 –0.06 1.01* 0.20 0.91* 1.01*
OmyOSU242 TC108885 Growth hormone (P87487; Oncorhynchus kisutch) 0.01 0.05 1.03* 0.33 1.30* 1.23*
OmyOSU1427 TC100257 Reticulon RTN9-A2 (Q6IEI9; O. mykiss) –0.03 0.18 1.95* 0.57 2.01* 1.80*
OmyOSU1428 TC103467 Reticulon RTN9-A1 (Q6IEJ0; O. mykiss) 0.01 0.26 1.72* 0.52 1.44* 1.57*
OmyOSU1588 TC96803 Viperin-like protein (Q5EEZ3; Channa argus) 0.10 0.08 1.17* 0.58 1.76* 1.76*
OmyOSU1068 TC118990 STAT 1-2 (O13132; O. mykiss) 0.13 0.11 1.10* 0.04 0.56 0.89*
OmyOSU1615 TC81096 TM4SF5 tumor antigen (AF281357; O. mykiss) –0.03 0.04 2.35* 0.28 0.66 0.95*
OmyOSU313 TC106070 Bone morphogenic protein 7 (S77477; Gallus gallus) –0.01 –0.04 –1.59* –0.10 –1.04* –1.24*
Protein stability and transport
OmyOSU139 TC128395 Cathepsin D (P87370; O. mykiss) 0.03 0.29 1.95* 0.64 1.50* 1.93*
OmyOSU1308 TC118879 Sec61 alpha form B (AF346601; O. mykiss) –0.05 –0.15 1.74* 0.14 0.95* 1.51*
OmyOSU933 TC115491 Chaperone protein GP96 (tumor rejection antigen) (Q7T3L3; D. rerio) 0.03 –0.25 1.14* 0.24 0.84* 0.92*
OmyOSU1306 TC109072 Sec61 alpha form A (AF346600; O. mykiss) 0.29 0.14 1.03* 0.09 0.53 0.83
OmyOSU1458 TC106687 Tubulin alpha-3 chain (P68365; Canis familiaris) –0.03 0.34 1.54* 0.26 0.37 1.00*
OmyOSU1460 TC98663 Beta tubulin (Q9DFT6; Notothenia coriiceps) 0.03 0.08 1.51* 0.01 0.06 0.89*
OmyOSU205 TC130693 Actin, cytoplasmic 1 (β-actin; O42161; Salmo salar) 0.15 0.14 1.14* 0.31 0.87* 0.79
OmyOSU1587 TC98530 Transgelin 2 (Q803W9; D. rerio) 0.07 0.14 0.94* –0.16 –0.08 –0.10
Nucleic acid metabolism
OmyOSU1518 TC131311 Similar to uridine phosphorylase 1 (XM_685152; D. rerio) 0.05 0.29 2.24* 1.55* 2.70* 3.01*
OmyOSU252 TC111966 Hypoxanthine phosphoribosyltransferase 1 (Q7ZV49; D. rerio) 0.13 0.24 1.65* 1.07* 2.29* 2.00*
OmyOSU1219 TC101340 Nucleoside diphosphate kinase (Q804Y0; O. mykiss) –0.01 0.12 1.15* 0.24 0.52 0.64
Transcription and translation
OmyOSU1439 TC107620 Translation factor sui1-like (Q2HYN5; Ictalurus punctatus) 0.01 0.45 0.97* 0.09 0.45 0.4
Immune function and acute-phase response
OmyOSU1147 TC115303 Pentraxin precursor (P79899; O. mykiss) 0.07 0.22 –1.29* –0.33 –0.93* –1.37*
OmyOSU1236 CR375493 Apopolysialoglycoprotein precursor (J04051; O. mykiss) 0.01 –0.51 –0.93* –0.37 –1.08* –0.73
OmyOSU1512 TC87050 Apolipoprotein A1 (AB183290; Fugu rubripes) –0.23 –0.96 –2.42* –0.43 –2.34* –0.51
OmyOSU878 CA367917 LECT2 neutrophil chemotactic factor (AF363272; O. mykiss) –0.14 –0.15 –0.87 –0.03 –1.94* –0.84
OmyOSU1469 TC8260 Cathepsin S (AY950578; Paralichthys olivaceus) 0.06 –0.50 –0.72 –0.33 –1.21* –0.85*
OmyOSU51 TC94755 IL-8 receptor (Q90VZ2; O. mykiss) –0.04 0.52 –1.01* 0.09 0.53 –0.90*
OmyOSU1669 NP814796 TNF receptor associated factor 2 (AJ548839; O. mykiss) 0.08 0.15 –0.37 –0.12 –1.22* –0.96*
OmyOSU232 TC91273 Differentially regulated trout protein (AF281355; O. mykiss) –0.34 –0.25 0.55 0.90 –1.58* 0.10
OmyOSU744 TC71412 Putative interlectin (AF281350; O. mykiss) –0.06 –0.06 –1.09* 0.40 –0.31 –0.15
OmyOSU401 NP543817 Complement component C5 (AF349001; O. mykiss) –0.06 0.05 –0.97* –0.04 –0.29 –0.61
OmyOSU411 TC97418 Complement component C9 (Q4QZ25; O. mykiss) 0.04 0.03 –0.94* –0.04 –0.37 –0.24
OmyOSU1648 TC113043 Haptoglobin 2 (Q9DFG0; O. mykiss) –0.01 0.46 –1.59* 0.36 –0.46 0.00
OmyOSU821 TC113043 Haptoglobin 2 (Q9DFG0; O. mykiss) –0.07 0.47 –1.79* 0.42 –0.52 –0.01
OmyOSU1564 TC100075 VHSV-induced protein-4 (Q8QGB4; O. mykiss) 0.00 0.65 3.75* 2.55* 3.98* 4.06*
OmyOSU1566 TC109185 VHSV-induced protein-6 (Q8QGB2; O. mykiss) 0.03 0.41 2.81* 1.81* 2.93* 3.27*
OmyOSU1580 TC104328 VHSV-induced protein (Q8QGA5; O. mykiss) –0.08 0.05 0.74 0.36 1.06* 1.04*
OmyOSU1576 TC94860 VHSV-induced protein-7 (Q8QGB7; O. mykiss) 0.07 –0.09 1.16* 0.46 0.93* 0.88*
OmyOSU1586 TC96479 VHSV-induced protein (Q8QGA4; O. mykiss) 0.13 0.35 1.22* 1.25* 0.75 0.79
OmyOSU634 TC110053 VHSV-induced C-lectin-like protein (Q8QGA9; O. mykiss) 0.04 0.02 1.15* 0.35 0.74 0.75
OmyOSU1584 NP543665 VHSV-induced protein (AF483543; O. mykiss) 0.10 0.46 1.39* 1.35* 0.65 0.66
OmyOSU1192 TC94749 Tapasin short form (Q3SAV0; O. mykiss) 0.12 –0.17 0.95* 0.18 0.40 0.69
OmyOSU567 TC126430 Chemokine CK-1 (Q9W691; O. mykiss) –0.02 0.01 2.52* –0.15 –0.02 –0.14
Continuedrelevant to PPs in trout liver because CLOF
did not result in an estrogenic response. In
other studies, the ability of PFOA to increase
serum E2 by hepatic aromatase was correlated
with the occurrence of rat Leydig cell tumors
in the absence of peroxisome proliferation
(Biegel et al. 2001). This mechanism is likely
also irrelevant for PFOA in trout because it did
not elevate serum E2. In comparison, serum E2
was increased after DHEA treatment, suggest-
ing that DHEA induces an estrogenic response
via indirect conversion of E2 by aromatase, as
described previously (Benninghoff and
Williams 2008). These data demonstrate that
PFOA enhances tumorigenesis through an
estrogenic mechanism unique among the PPs
investigated in this study.
The potential for PFOA and other struc-
turally similar perfluorinated chemicals to
promote hepatocarcinogenesis via direct inter-
actions with the trout hepatic ER is the subject
Tumor promotion by PFOA
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Figure 3. Comparison of gene expression of CYP2K5, VTG, CTSD, CYP1A, and ESR1 measured by microarray and real-time qRT-PCR. Values are expressed as fold
change (log2; mean ± SD) compared with vehicle control. Dashed lines indicate 1.8-fold change (± 0.847 log2). 
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Table 3. Continued
Treatment (ppm) 
CLOF DHEA PFOA PFOA E2
Array ID DFCI IDa Gene name (accession number; species)b Control 1,800 750 500 1,800 5
Metabolism/homeostasis (drug, lipid, fatty acid, retinol) 
OmyOSU1389 TC95312 CYP2K5 (AAC28309; O. mykiss) 0.05 2.02* 0.40 0.87* 1.95* –1.47*
OmyOSU146 TC63282 CYP1A (AF059711; O. mykiss) 0.04 –0.58 –1.11* –0.60 –0.94* –0.68
OmyOSU147 NP543804 CYP3A45 (AF267126; O. mykiss) 0.04 0.76 –1.00* 0.14 0.63 –0.93*
OmyOSU343 TC69983 Biotinidase fragment 2 (AF281333; O. mykiss) –0.01 –0.07 –1.68* –0.18 –1.14* –1.52*
OmyOSU1131 TC105248 Arylamine N-acetyl transferase (Q3ZLG1; Oreochromis mossambicus) 0.05 0.50 –1.30* –0.41 –0.67 –1.01*
OmyOSU153 TC89948 Liver fatty acid binding protein (AF281344; O. mykiss) –0.10 0.33 1.67* 0.49 0.45 0.75
OmyOSU875 TC98662 Glucokinase (O93314; O. mykiss) –0.03 0.60 1.87* 0.45 0.49 1.92*
OmyOSU873 TC98662 Glucokinase (O93314; O. mykiss) 0.06 0.58 1.65* 0.38 0.39 1.66*
OmyOSU249 TC106837 Succinate dehydrogenase, subunit A (Q7ZVF3; D. rerio) –0.12 0.10 1.44* 0.98* 1.93* 1.92*
OmyOSU245 TC112292 Succinate dehydrogenase, subunit A (Q6TNQ9; D. rerio) 0.01 0.15 1.21* 0.76 1.75* 1.78*
OmyOSU1631 TC98907 Prostaglandin D synthase (Q9DFD7; O. mykiss) –0.04 0.91* 1.16* 0.36 0.85* 0.25
OmyOSU847 TC94773 Carbonyl reductase/HSD20BA (Q9PT36; O. mykiss) 0.09 0.63 0.16 0.52 1.05* 0.04
OmyOSU547 TC111036 Carnitine O-palmitoyltransferase II (Q5U3U3; D. rerio) –0.00 –0.17 –0.00 –0.15 –0.00 –0.08
OmyOSU327 TC96499 Acetyl-CoA acetyltransferase 2 (Q5SPA3; D. rerio) 0.00 –0.02 0.02 0.05 –0.18 –0.05
Redox regulation
OmyOSU238 TC56389 Glutathione peroxidase 4 (AAO86704; D. rerio) 0.02 0.08 0.84* 0.55 1.16* 1.46*
OmyOSU37 TC101266 Catalase (AF170069; D. rerio) –0.09 –0.19 –0.69 –0.43 –0.54 –0.69
Miscellaneous
OmyOSU1034 TC111169 SOX-LZ (Q91215; O. mykiss) 0.02 0.97 0.92* 0.77 2.32* 1.15*
OmyOSU488 TC97895 DMRT4 protein (AF209097; O. mykiss) 0.02 0.43 0.74 0.31 1.41* 0.82
OmyOSU486 NP543963 DMRT2 protein (AF209096; O. mykiss) 0.00 –0.06 –0.99* –0.20 –1.29* –1.33*
OmyOSU243 TC110554 Ictacalcin (Q4JI13; I. punctatus) 0.01 0.17 1.86* –0.02 0.17 –0.08
OmyOSU572 TC116478 COX6A mitochondrial precursor (O13085; O. mykiss) 0.06 0.14 –1.17* –0.12 0.25 –0.15
OmyOSU544 TC105829 Small EDRK-rich factor 2 (P84101; Homo sapiens) –0.02 –0.02 –1.30* –0.04 –1.67* –1.46*
Abbreviations: DMRT4, DM-related transcription factor 4; EGF, epidermal growth factor; IL, interleukin; TNF, tumor necrosis factor; VHSV, viral hemorrhagic septicemia virus. Values
shown are average fold change values (log2) that represent background-corrected, LOWESS-normalized signal ratios. 
aDFCI Gene Index ID number of the tentative consensus or singleton expressed sequence tag sequence corresponding to the OSUrbt, version 2, microarray feature. bData shown are the
most signiﬁcant BLASTX (NCBI 2008a); however, if an expressed sequence tag has no signiﬁcant (E-value < 10–6) BLASTX hit, then the most signiﬁcant BLASTN hit is shown. Genes have
been categorized by function based on putative trout homolog using the Gene Ontology and OMIM databases (NCBI 2008b, 2008c). Animals were fed 0.1% DMSO vehicle (CON), 1,800 ppm
CLOF, 750 ppm DHEA, or 500 or 1,800 ppm PFOA acid (low or high PFOA, respectively), or 5 ppm E2 in the diet for 14 days. *p < 0.05 by Welch’s t-test for genes regulated at least 1.8-fold. of ongoing studies in our laboratory.
Evidence for activation of ER by PFOA,
perfluorooctanyl sulfonate, and several fluo-
rotelomer alcohols is supported by data that
the ER antagonist tamoxifen inhibits their
estrogenic activity in primary tilapia hepato-
cytes in vitro (Liu et al. 2007). Up-regulation
of ER-α and ER-β expression was also
reported in human MCF-7 cells and Chinese
rare minnow, respectively, after exposure to
PFOA (Maras et al. 2006; Wei et al. 2007).
However, PFOA does not transactivate
human ER-α or ER-β or Japanese medaka
ER-α in yeast two-hybrid assays, suggesting
that either species selectivity in ER binding or
indirect activation of ER may be occurring
(Ishibashi et al. 2007, 2008). Cross-talk
between nuclear receptors PPARγ, PPARα,
and ER has been described in mouse uterus
(Gunin et al. 2004), and PFOA activation of
other nuclear receptors, including constitutive
androstane receptor and pregnenolone X
receptor, was reported in PPARα-null mice,
possibly leading to hepatomegaly in these ani-
mals (Anderson et al. 2007). Therefore,
although the majority of the hepatic effects of
PFOA are mediated by PPARα in PP-sensitive
models, interaction of PFOA with other
nuclear receptors, including ER, may be func-
tionally significant in liver of PP-insensitive
models or in other target organs and merits
further investigation.
It is clear that the speciﬁc mechanism for
PFOA estrogenicity will be important in
extrapolating these data across species; how-
ever, our current study provides evidence that
animals lacking peroxisome proliferation
activity are rather insensitive to carcinogenesis
by PFOA. Only 50 mg/kg/day (1,800 ppm)
PFOA resulted in tumor enhancement, indi-
cating that chronic exposure to high levels of
PFOA are necessary to promote hepato-
carcinogenesis in trout, which are sensitive to
liver tumor promotion by estrogens. These
doses are typical of those used in rodent can-
cer studies with PPARα agonists but higher
than the low part-per-billion PFOA concen-
trations measured in human and environmen-
tal samples (Calafat et al. 2007; Houde et al.
2006). Although our study did not identify a
threshold for the estrogenic effects of PFOA
in trout liver, we observed only 26% overlap
of gene signatures between 5 ppm E2 and
500 ppm (5 mg/kg/day) PFOA compared
with 83% at 1,800 ppm PFOA. These data
demonstrate that PFOA is a weak estrogen in
trout, similar to observations from other
models in which PFOA weakly induced ER
gene targets and also antagonized the estro-
genic activity of E2 (Liu et al. 2007; Maras
et al. 2006). Further studies are necessary to
evaluate the potential for PFOA-mediated
carcinogenesis in other PP-insensitive species,
and in light of the mechanism identified in
this study, the consequences of hormone-
related effects by PFOA should be also con-
sidered in other tissues, models, and sensitive
life stages.
Conclusions
We report the novel ﬁndings that PFOA can
enhance hepatocarcinogenesis postinitiation in
rainbow trout, a model that is insensitive to
peroxisome proliferation. Tumorigenesis was
not related to the function of PFOA as a PP or
PPARα agonist and was not observed after
treatment with CLOF. Rather, tumor out-
come was phenotypically linked to estrogenic
gene signatures in trout liver after molecular
proﬁling, which showed excellent correlation
with E2 and is a unique mechanism action
identiﬁed for PFOA in carcinogenesis. 
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